Adare Pharmaceuticals: Improving solubility. Creating new possibilities for patients.
The bioavailability of a drug is strongly dependent on its solubility in the gastrointestinal tract. At Adare, we have proprietary technologies available to help improve the solubility of oral drugs. BioriseTM Bioavailability Enhancement Technology
The bioavailability of a drug is strongly dependent on its solubility in the gastrointestinal tract. At Adare, we have proprietary technologies available to help improve the solubility of oral drugs.
Biorise™ Bioavailability Enhancement Technology
Biorise™ Bioavailability Enhancement Technology is used to enhance bioavailability of drugs that are poorly soluble at physiological pHs.
This technology creates new physical entities (NPEs) with better solubility profiles. These NPEs are produced by breaking down the crystalline drug into nanocrystals and/or amorphous (non-crystalline) drug particles that are stabilized in a carrier system to maintain the drug in its activated form for the duration of its shelf life.
This approach transforms the original crystalline form of the drug into an amorphous and/or nanocrystalline, thermodynamically activated solid form-characterized by higher solubility-thereby enhancing the rate and extent of absorption in the gastrointestinal tract.
With a broad range of proprietary technologies, Adare can help you overcome formulation challenges. To learn more about Biorise™ Bioavailability Enhancement Technology and our other proprietary technologies, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com.
©2015 Adare Pharmaceuticals, Inc.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
